HCP Perspectives on Metabolic Diseases (US & EU)
This survey of 50 healthcare professionals across the US and Europe highlights the growing burden of metabolic diseases, particularly type 2 diabetes and obesity, which are the most commonly managed conditions. Over 90% of HCPs report high disease prevalence, underscoring the urgency of effective management strategies.
The findings reveal that patient adherence and lifestyle modification challenges are the biggest barriers to successful treatment. While traditional therapies like metformin remain widely used, there is a clear shift toward advanced treatments such as GLP-1 receptor agonists and SGLT2 inhibitors.
Despite progress, only a minority of HCPs are fully satisfied with patient outcomes, indicating significant unmet needs. Regional differences show higher adoption of innovative therapies in the US, while Europe places more emphasis on guidelines and cost considerations.
Overall, the survey emphasizes the need for patient-centric care, improved access to therapies, and multidisciplinary approaches to better manage metabolic diseases.
Objective
- Awareness and perception of metabolic diseases
- Treatment approaches and challenges
- Views on emerging therapies
- Regional differences (US vs EU)
Methodology
- Sample size: 50 HCPs
- Regions:
- US: 25 respondents
- EU: 25 respondents
- Specialties: Endocrinologists, General Physicians, Cardiologists
- Method: Online structured questionnaire
- Duration: ~10–12 minutes
Survey Results
Q1. Which metabolic conditions do you most commonly manage?
- Type 2 Diabetes – 90%
- Obesity – 78%
- Dyslipidemia – 64%
- Metabolic Syndrome – 58%
- NAFLD/NASH – 42%
Insight: Type 2 diabetes dominates clinical focus, but obesity is rapidly increasing in relevance.
Q2. How would you rate the prevalence of metabolic diseases in your practice?
- Very High – 62%
- High – 28%
- Moderate – 10%
- Low – 0%
Insight: 90%+ HCPs perceive metabolic diseases as a major burden.
Q3. What are the biggest challenges in managing metabolic diseases?
- Patient adherence – 72%
- Lifestyle modification compliance – 68%
- Limited time for counseling – 54%
- Cost of treatment – 46%
- Lack of multidisciplinary support – 38%
Insight: Behavioral and adherence issues outweigh purely clinical barriers.
Q4. How confident are you in current treatment guidelines?
- Very confident – 36%
- Somewhat confident – 48%
- Neutral – 12%
- Not confident – 4%
Insight: Most HCPs trust guidelines but still see room for improvement.
Q5. Which therapies do you frequently prescribe?
- Metformin – 88%
- GLP-1 receptor agonists – 66%
- SGLT2 inhibitors – 62%
- Insulin – 58%
- Lifestyle intervention alone – 40%
Insight: Shift toward GLP-1 and SGLT2 therapies, especially in US.
Q6. Awareness of newer therapies (e.g., GLP-1 analogs, dual agonists)
- Very aware – 52%
- Moderately aware – 34%
- Slightly aware – 10%
- Not aware – 4%
Insight: Strong awareness, but depth of understanding varies.
Q7. What factors influence your treatment decisions most?
- Clinical efficacy – 82%
- Safety profile – 76%
- Patient affordability – 60%
- Guidelines – 58%
- Patient preference – 42%
Insight: Clinical outcomes dominate, but cost remains a major constraint.
Q8. How do patients respond to lifestyle interventions?
- Very effective – 18%
- Moderately effective – 46%
- Slightly effective – 28%
- Not effective – 8%
Insight: Lifestyle changes are important but inconsistently successful.
Q9. Are you satisfied with current patient outcomes?
- Very satisfied – 22%
- Somewhat satisfied – 48%
- Neutral – 20%
- Dissatisfied – 10%
Insight: Only ~70% satisfaction, indicating unmet needs.
Regional Comparison (US vs EU)
| Aspect | US | EU |
|---|---|---|
| Use of GLP-1 therapies | Higher (72%) | Moderate (60%) |
| Cost concerns | Moderate | High |
| Guideline adherence | Slightly lower | Higher |
| Lifestyle emphasis | Moderate | Strong |
Insight:
• US: More adoption of innovative therapies
• EU: Stronger reliance on structured guidelines and lifestyle care
